NEW YORK (GenomeWeb News) – GE Healthcare said today it has signed an agreement giving the drugmaker Merck access to a molecular imaging agent GE is developing for high-speed, quantitative lung imaging.
 
The company said the collaborators will evaluate GE Healthcare’s Spin Signal Technology to determine if it can help researchers study the functioning of diseased lungs using modified xenon gas in conjunction with magnetic resonance imaging scans.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.